- AbbVie Inc ABBV beat Wall Street consensus for first-quarter revenue & earnings and raised its full-year profit forecast, helped by demand for its rheumatoid arthritis drug, Humira, and newer treatments such as psoriasis treatment Skyrizi.
- It reported an adjusted EPS of $2.95, which beat the analyst consensus estimate of $2.83
- Sales of $13.01 billion also surpassed the analyst consensus estimate of $12.76 billion and increased 50% over sales of $8.62 billion in the same period last year.
- Consolidated Humira sales rose 3.5% to $4.87 billion. However, they fell 8.3% in markets outside the U.S. due to increasing biosimilar competition.
- AbbVie is banking on newer treatments such as Skyrizi and rheumatoid arthritis drug Rinvoq.
- Sales of Skyrizi surged about 91% to $574 million, while Rinvoq almost doubled to $303 million.
- Sales of Botox, which AbbVie gained through its $63 billion deal for Allergan, rose 44.7% to $447 million as a treatment for wrinkles and other cosmetic uses. The drug generated sales of $532 million as a therapeutic treatment.
- Sales of the anti-wrinkle injection had been hit last year due to the COVID-19 pandemic as people avoided non-urgent medical procedures.
- Guidance: AbbVie raised its full-year adjusted earnings forecast to between $12.37 and $12.57 per share, from its prior estimate of $12.32 to $12.52. Analysts anticipated an adjusted EPS of $12.45.
- It forecasts GAAP diluted EPS guidance of $7.27 to $7.47 versus prior guidance of $6.69 to $6.89.
- Price Action: ABBV shares are trading 1.7% higher at $112.78 in the premarket trading on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
